Epidiolex

Phase 2Small molecule

Jazz Pharmaceuticals

Epidiolex is one of 85 small molecule programs targeting Sanfilippo Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Sanfilippo SyndromeRecruiting

CBDRecruiting

Total Knee ArthroplastyRecruiting

AutismActive, not recruiting

OrthopedicRecruiting

Sanfilippo SyndromePreclinical

Recruiting

CBDPhase 1

Recruiting

Total Knee ArthroplastyPhase 2

Recruiting

AutismPhase 2

Active, not recruiting

OrthopedicPhase 2

Recruiting

Competition

Competitive Landscape

66 competitors in Total Knee Arthroplasty

#DrugCompanyPhaseTrials

Naropin

FFresenius Kabi USA, LLC

Approved

26 2

Cyklokapron

JJ Molner

Approved

26 3

Marcaine

IInnocoll

Approved

18 4

Decadron

AAspen Global Incorporated

Approved

18 5

Medrol

Pfizer

Approved

4 6

Lexapro

AbbVie

Approved

1 7

Journavx

Vertex Pharmaceuticals

Approved

1 8

Duragesic

CCephalon

Approved

7 9

MS Contin

HHikma Pharmaceuticals LLC

Approved

7 10

Celebrex

PPhiladelphia Eye Associates

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Orthopedic

NCT06381791

Q4 2028

PreclinicalRecruiting

Sanfilippo Syndrome

NCT06333041

Q1 2029

Phase 2Recruiting

Total Knee Arthroplasty

NCT06234631

Q3 2029

Phase 1Recruiting

CBD

NCT07001930

Clinical

Trials by Indication[1]

CBD2 trials

Investigation of the Pharmacokinetic Profile of CBD

Completed·YYasmin Hurd·Phase 1·NCT05269706·60 enrolled

Pharmacological Effects of Cannabidiol on Responses to Stress and Nicotine Withdrawal

Recruiting·JJohns Hopkins University·Phase 1·NCT07001930·90 enrolled

Orthopedic1 trial

CBD for Pain Following Orthopedic Shoulder Surgery

Recruiting·TThe Methodist Hospital Research Institute·Phase 1/2·NCT06381791·80 enrolled

Opioid Withdrawal1 trial

Oral Cannabidiol for Opioid Withdrawal

Completed·JJohns Hopkins University·Phase 1/2·NCT04238754·3 enrolled

Total Knee Arthroplasty1 trial

Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty

Recruiting·CChad Brummett·Phase 2·NCT06234631·380 enrolled

Autism1 trial

Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism

Active, not recruiting·UUniversity of California, San Diego·Phase 2·NCT04517799·42 enrolled

6 more indications

Long-term Follow-up1 trial

Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting

Active, not recruiting· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals··NCT05772429·158 enrolled

Bipolar Disorder1 trial

Effects of Cannabis on Cognition and Endocannabinoid Levels in Bipolar Disorder Patients and Healthy Volunteers

Terminated·UUniversity of California, San Diego·Phase 1·NCT04231643·19 enrolled

Adult1 trial

University of Alabama at Birmingham (UAB) Adult CBD Program

Completed·UUniversity of Alabama at Birmingham·Phase 1·NCT02700412·80 enrolled

Pediatric1 trial

University of Alabama at Birmingham (UAB) Pediatric CBD Program

Completed·UUniversity of Alabama at Birmingham·Phase 1·NCT02695537·89 enrolled

Sanfilippo Syndrome1 trial

Randomized, Double-Blind, Placebo-Controlled Cross-Over Study to Evaluate the Effects of Cannabidiol on Neurobehavioral and Function Outcomes in Sanfilippo Syndrome

Recruiting·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Preclinical·NCT06333041·35 enrolled

Maternal Complications1 trial

Observational Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy to Assess the Risk of Pregnancy and Maternal Complications and Other Events of Interest on the Developing Fetus, Neonate, and Infant

Recruiting· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals··NCT06113237·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Epidiolex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Epidiolex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Epidiolex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jazz Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Jazz Pharmaceuticals

Epidiolex

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2028

Q1 2029

Q3 2029

Trials by Indication[1]

CBD2 trials

Orthopedic1 trial

Opioid Withdrawal1 trial

Total Knee Arthroplasty1 trial

Autism1 trial

Long-term Follow-up1 trial

Bipolar Disorder1 trial

Adult1 trial

Pediatric1 trial

Sanfilippo Syndrome1 trial

Maternal Complications1 trial

References

Drug Info

Quick Facts

Related News